Literature DB >> 19278835

Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint.

Olaf Burkhardt, Kerstin Rauch, Volkhard Kaever, Johannes Hadem, Jan T Kielstein, Tobias Welte.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19278835     DOI： 10.1016/j.ijantimicag.2009.01.015

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


× No keyword cloud information.
  30 in total

Review 1.  Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.

Authors:  Nadim G El Chakhtoura; Elie Saade; Alina Iovleva; Mohamad Yasmin; Brigid Wilson; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2018-01-16       Impact factor: 5.091

2.  Novel treatment approach to combat an infection with Acinetobacter.

Authors:  Jeffrey S Stroup; Kendal Mitchell; David Hitzeman
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-01

3.  Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia.

Authors:  Julio Ramirez; Nathalie Dartois; Hassan Gandjini; Jean Li Yan; Joan Korth-Bradley; Paul C McGovern
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

Review 4.  Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.

Authors:  Elizabeth A Neuner; Jason C Gallagher
Journal:  Virulence       Date:  2016-08-09       Impact factor: 5.882

Review 5.  Carbapenem-Resistant Gram-Negative Bacterial Infections in Children.

Authors:  David Aguilera-Alonso; Luis Escosa-García; Jesús Saavedra-Lozano; Emilia Cercenado; Fernando Baquero-Artigao
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

6.  Task force on management and prevention of Acinetobacter baumannii infections in the ICU.

Authors:  José Garnacho-Montero; George Dimopoulos; Garyphallia Poulakou; Murat Akova; José Miguel Cisneros; Jan De Waele; Nicola Petrosillo; Harald Seifert; Jean François Timsit; Jordi Vila; Jean-Ralph Zahar; Matteo Bassetti
Journal:  Intensive Care Med       Date:  2015-10-05       Impact factor: 17.440

7.  High dose of tigecycline for extremely resistant Gram-negative pneumonia: yes, we can.

Authors:  José Garnacho-Montero; Carmen Ferrándiz-Millón
Journal:  Crit Care       Date:  2014-06-24       Impact factor: 9.097

Review 8.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

Review 9.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

10.  Colistin-tigecycline versus colistin-imipenem-cilastatin combinations for the treatment of Acinetobacter baumannii ventilator-acquired pneumonia: a prognosis study.

Authors:  Anis Chaari; Tài Pham; Basma Mnif; Kamilia Chtara; Fatma Medhioub; Najeh Baccouche; Mabrouk Bahloul; Adnène Hammami; Mounir Bouaziz
Journal:  Intensive Care Med       Date:  2015-08-12       Impact factor: 17.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.